Stocklytics Platform
Asset logo for symbol AMLX
Amylyx Pharmaceuticals
AMLX55
$4.05arrow_drop_up2.52%$0.09
Asset logo for symbol AMLX
AMLX55

$4.05

arrow_drop_up2.52%

Performance History

Chart placeholder
Key Stats
Open$3.98
Prev. Close$3.96
EPS-3.82
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$277.61M
PE Ratio-
LOWHIGH
Day Range3.71
4.19
52 Week Range1.57
19.94
Ratios
Revenue-
EPS-3.82

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About Amylyx Pharmaceuticals (AMLX)

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) is a biopharmaceutical company focused on developing innovative treatments for neurodegenerative diseases. The company's mission is to improve the lives of patients and their families who are affected by these devastating conditions. With a strong commitment to scientific excellence, Amylyx is dedicated to advancing its pipeline of potential therapies that address the underlying causes of neurodegeneration. The company's lead investigational product candidate, AMX0035, is currently being evaluated in clinical trials for the treatment of amyotrophic lateral sclerosis (ALS) and Alzheimer's disease. AMX0035 is a combination therapy that targets multiple pathways implicated in neurodegeneration, with the goal of preserving and protecting neurons and preventing disease progression.
In addition to AMX0035, Amylyx has a robust pipeline of other potential therapies for neurodegenerative diseases. The company is actively exploring the development of treatments for conditions such as Parkinson's disease, multiple sclerosis, and frontotemporal dementia. By leveraging its deep understanding of the biology of neurodegeneration, Amylyx aims to create transformative therapies that have the potential to significantly impact patients' lives. With a market capitalization of over $1 billion, Amylyx is well-positioned to continue advancing its research and development efforts. The company's financial strength and strategic partnerships provide a solid foundation for future growth and success.
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Joshua B. Cohen
Headquarters
Cambridge
Employees
338
Exchange
NASDAQ
add Amylyx Pharmaceuticals to watchlist

Keep an eye on Amylyx Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Amylyx Pharmaceuticals's (AMLX) price per share?

The current price per share for Amylyx Pharmaceuticals (AMLX) is $4.05. The stock has seen a price change of $0.1 recently, indicating a 2.53% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Amylyx Pharmaceuticals (AMLX)?

For Amylyx Pharmaceuticals (AMLX), the 52-week high is $19.95, which is 392.57% from the current price. The 52-week low is $1.58, the current price is 157.14% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Amylyx Pharmaceuticals (AMLX) a growth stock?

Amylyx Pharmaceuticals (AMLX) has shown an average price growth of -4.38% over the past three years. It has received a score of -3 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Amylyx Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Amylyx Pharmaceuticals (AMLX) stock price performance year to date (YTD)?

As of the latest data, Amylyx Pharmaceuticals (AMLX) has a year-to-date price change of -72.95%. Over the past month, the stock has experienced a price change of -22.56%. Over the last three months, the change has been 30.65%. Over the past six months, the figure is 145.45%.
help

Is Amylyx Pharmaceuticals (AMLX) a profitable company?

Amylyx Pharmaceuticals (AMLX) has a net income of $49.27M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 93.32% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -18.19K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. The gross profit is $355.34M. Operating income is noted at $38.8M. Furthermore, the EBITDA is $39.89M.
help

What is the market capitalization of Amylyx Pharmaceuticals (AMLX)?

Amylyx Pharmaceuticals (AMLX) has a market capitalization of $277.62M. The average daily trading volume is 4.06, indicating the stock's liquidity and investor engagement.

Take Your Investments to a Whole New Level